Published by Independent Med Management (IMM)  |  Reading time: 6 minutes

A medication review should change the trajectory of a claim. If it does not, something is wrong with the review, not the concept.

Too many reviews in Workers’ Compensation amount to little more than a list of what the claimant is taking. They confirm the obvious, sit in a file, and nobody acts on them. The cost of the review gets absorbed into the claim, and nothing changes.

This article sets out what a genuinely useful medication review looks like in a WC environment, the outcomes it should produce, and the questions you should be asking any provider before you engage them.

Five Things That Separate a Good Review from a Wasted One

After more than a decade of delivering pharmacy reviews across Australian Workers’ Compensation and CTP claims, we have seen the full spectrum. The reviews that actually shift claim outcomes share five characteristics:

• Independence from the supply chain: The reviewer cannot have a financial relationship with the prescriber or the dispensing pharmacy. Even the perception of a conflict undermines everything that follows. If the pharmacist reviewing the medications is also the one selling them, the review is compromised before it starts.
• Full-regime clinical depth: Reviewing only claim-related medications misses the picture entirely. Non-claim medications interact with claim-related scripts in ways that affect sedation, cognition, fall risk, and physical capacity. A review that ignores half the medication list is half a review.
• Plain-English output: A report written in dense clinical language for an audience of case managers is a report that will not be actioned. The best reviews translate clinical findings into clear, prioritised recommendations that non-clinicians can pick up and run with.
• Prescriber engagement that actually lands: Writing a recommendation is easy. Getting a GP to act on it is the hard part. Providers with consistently high prescriber implementation rates are proving that their recommendations are clinically sound and communicated in a way that respects the treating relationship.
• Return-to-work lens: Every finding should be assessed against the claimant’s functional capacity and recovery trajectory. A review that identifies a drug interaction but says nothing about how it affects the return-to-work plan has missed the point of why the insurer requested it.

What an IMM Review Actually Covers

Independent Med Management (IMM) was built specifically for this environment. Our reviews are conducted by accredited clinical pharmacists who work exclusively in the personal injury space. They understand scheme requirements, claims workflows, and what a case manager actually needs from a report.

The Numbers Behind the Reviews

IMM publishes outcome data because it matters. These are not projections. They reflect real-world results from pharmacy reviews delivered across Australian WC claims:

The 81% prescriber implementation rate is the number that matters most. It means that four out of five times, the treating GP reads the review, agrees with the clinical reasoning, and changes their prescribing accordingly. That is not a report sitting in a file. That is clinical practice being redirected.

Where the Risk Actually Sits: High-Risk Drug Categories

Workers’ Compensation claims are disproportionately exposed to medications with dependency, sedation, and cognitive impairment risk. The following categories should be front and centre in any review.

Opioids

Long-term opioid prescribing in WC is common, persistent, and frequently counterproductive. The evidence is unambiguous: prolonged opioid use for musculoskeletal injury does not improve functional outcomes. It is associated with delayed return to work, increased psychological comorbidity, opioid-induced hyperalgesia, and physical dependency. A rigorous review will assess whether ongoing prescribing is clinically justified, identify safer alternatives, and lay out a realistic titration plan the GP can implement.

Benzodiazepines and Z-Drugs

Sedative hypnotics including benzodiazepines (diazepam, oxazepam, clonazepam) and z-drugs (zolpidem, zopiclone) are commonly prescribed for sleep and anxiety in WC claimants. The risks are significant: cognitive impairment, falls, rebound insomnia, and dependency that becomes progressively harder to manage the longer the prescribing continues. Long-term use is rarely appropriate, and reviews should assess the feasibility and timing of gradual dose reduction.

Antidepressants

Antidepressants are widely used in WC for pain, sleep, and mood. In some cases they are appropriate. In many, they are continued well beyond the recommended duration without reassessment. Sedating antidepressants in particular, such as amitriptyline and mirtazapine, can significantly impair work capacity while offering diminishing therapeutic benefit over time.

Alignment with Australian Regulatory Frameworks

IMM reviews are conducted in alignment with the regulatory and clinical governance frameworks that insurers operate within:

• SIRA NSW guidelines, including the Medication Management Best Practice Guide and whiplash-associated disorder frameworks
• RACGP and Australian Pain Society guidance on opioid prescribing
• TGA requirements including relevant clinician information sheets
• State-specific return-to-work legislative obligations across all jurisdictions

This matters because it means recommendations are defensible. When a case manager takes an IMM finding to a treating practitioner or into a file review, it is grounded in the same frameworks the insurer is accountable to.

Five Questions to Ask Any Provider Before You Engage Them

Not every pharmacy review provider is built for the insurance environment. Before committing to a service, put these questions to them:

• What is your prescriber implementation rate? This is the single most meaningful measure of whether a review actually changes anything. If a provider cannot answer this question with data, that tells you something.
• Do your pharmacists have WC-specific experience? Pharmacy review for personal injury is a specialist field. Generalist pharmacists may produce clinically accurate reports that are operationally useless because they lack the claims context to prioritise findings effectively.
• How do you communicate with treating doctors? A review that never reaches the GP, or reaches them as a cold document with no context, will not be actioned. Ask about GP communication protocols and whether direct pharmacist-to-GP contact is available.
• What is your turnaround? Complex claims need timely information. Two to five business days from receipt of records is a reasonable benchmark. Anything longer and the claim has often moved past the point where the review is useful.
• Can reviews be escalated? Some claims need follow-up reviews, pharmacist-to-GP calls, or ongoing medication management coordination. Check whether the provider offers these or whether it is a one-and-done service.

Summary

The best medication reviews for Workers’ Compensation do not just describe what is happening. They change what happens next. They are independent, clinically rigorous, written for the people who actually need to act on them, and oriented entirely around recovery and return to work.

IMM was built for this. If medication management is a concern on your claim, a review is the fastest path to clinical clarity and a concrete plan of action.

Independent Med Management (IMM) provides pharmacy review and medication risk governance services to Workers’ Compensation and CTP insurers across Australia. This article is for general information purposes. Clinical decisions should be made in consultation with qualified health professionals.